Inverse relationship between brain noradrenaline level and dopamine loss in Parkinson disease: a possible neuroprotective role for noradrenaline.
Identifieur interne : 001124 ( PubMed/Curation ); précédent : 001123; suivant : 001125Inverse relationship between brain noradrenaline level and dopamine loss in Parkinson disease: a possible neuroprotective role for noradrenaline.
Auteurs : Junchao Tong [Canada] ; Oleh Hornykiewicz ; Stephen J. KishSource :
- Archives of neurology [ 0003-9942 ] ; 2006.
English descriptors
- KwdEn :
- Aged, Antiparkinson Agents (therapeutic use), Autopsy, Brain Chemistry (physiology), Case-Control Studies, Dopamine (metabolism), Female, Humans, Levodopa (therapeutic use), Locus Coeruleus (pathology), Male, Norepinephrine (metabolism), Nucleus Accumbens (metabolism), Parkinson Disease (metabolism), Substantia Nigra (pathology).
- MESH :
- chemical , metabolism : Dopamine, Norepinephrine.
- chemical , therapeutic use : Antiparkinson Agents, Levodopa.
- metabolism : Nucleus Accumbens, Parkinson Disease.
- pathology : Locus Coeruleus, Substantia Nigra.
- physiology : Brain Chemistry.
- Aged, Autopsy, Case-Control Studies, Female, Humans, Male.
Abstract
Experimental findings using animal models of Parkinson disease (PD) suggest that noradrenaline might protect dopamine neurons from damage.
DOI: 10.1001/archneur.63.12.1724
PubMed: 17172611
Links toward previous steps (curation, corpus...)
- to stream PubMed, to step Corpus: Pour aller vers cette notice dans l'étape Curation :001124
Links to Exploration step
pubmed:17172611Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Inverse relationship between brain noradrenaline level and dopamine loss in Parkinson disease: a possible neuroprotective role for noradrenaline.</title><author><name sortKey="Tong, Junchao" sort="Tong, Junchao" uniqKey="Tong J" first="Junchao" last="Tong">Junchao Tong</name><affiliation wicri:level="1"><nlm:affiliation>Human Neurochemical Pathology Laboratory, Centre for Addiction and Mental Health, Toronto, Ontario, Canada. junchao_tong@camh.net</nlm:affiliation><country xml:lang="fr">Canada</country><wicri:regionArea>Human Neurochemical Pathology Laboratory, Centre for Addiction and Mental Health, Toronto, Ontario</wicri:regionArea></affiliation></author><author><name sortKey="Hornykiewicz, Oleh" sort="Hornykiewicz, Oleh" uniqKey="Hornykiewicz O" first="Oleh" last="Hornykiewicz">Oleh Hornykiewicz</name></author><author><name sortKey="Kish, Stephen J" sort="Kish, Stephen J" uniqKey="Kish S" first="Stephen J" last="Kish">Stephen J. Kish</name></author></titleStmt><publicationStmt><idno type="wicri:source">PubMed</idno><date when="2006">2006</date><idno type="RBID">pubmed:17172611</idno><idno type="pmid">17172611</idno><idno type="doi">10.1001/archneur.63.12.1724</idno><idno type="wicri:Area/PubMed/Corpus">001124</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Corpus" wicri:corpus="PubMed">001124</idno><idno type="wicri:Area/PubMed/Curation">001124</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Curation">001124</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en">Inverse relationship between brain noradrenaline level and dopamine loss in Parkinson disease: a possible neuroprotective role for noradrenaline.</title><author><name sortKey="Tong, Junchao" sort="Tong, Junchao" uniqKey="Tong J" first="Junchao" last="Tong">Junchao Tong</name><affiliation wicri:level="1"><nlm:affiliation>Human Neurochemical Pathology Laboratory, Centre for Addiction and Mental Health, Toronto, Ontario, Canada. junchao_tong@camh.net</nlm:affiliation><country xml:lang="fr">Canada</country><wicri:regionArea>Human Neurochemical Pathology Laboratory, Centre for Addiction and Mental Health, Toronto, Ontario</wicri:regionArea></affiliation></author><author><name sortKey="Hornykiewicz, Oleh" sort="Hornykiewicz, Oleh" uniqKey="Hornykiewicz O" first="Oleh" last="Hornykiewicz">Oleh Hornykiewicz</name></author><author><name sortKey="Kish, Stephen J" sort="Kish, Stephen J" uniqKey="Kish S" first="Stephen J" last="Kish">Stephen J. Kish</name></author></analytic><series><title level="j">Archives of neurology</title><idno type="ISSN">0003-9942</idno><imprint><date when="2006" type="published">2006</date></imprint></series></biblStruct></sourceDesc></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Aged</term><term>Antiparkinson Agents (therapeutic use)</term><term>Autopsy</term><term>Brain Chemistry (physiology)</term><term>Case-Control Studies</term><term>Dopamine (metabolism)</term><term>Female</term><term>Humans</term><term>Levodopa (therapeutic use)</term><term>Locus Coeruleus (pathology)</term><term>Male</term><term>Norepinephrine (metabolism)</term><term>Nucleus Accumbens (metabolism)</term><term>Parkinson Disease (metabolism)</term><term>Substantia Nigra (pathology)</term></keywords><keywords scheme="MESH" type="chemical" qualifier="metabolism" xml:lang="en"><term>Dopamine</term><term>Norepinephrine</term></keywords><keywords scheme="MESH" type="chemical" qualifier="therapeutic use" xml:lang="en"><term>Antiparkinson Agents</term><term>Levodopa</term></keywords><keywords scheme="MESH" qualifier="metabolism" xml:lang="en"><term>Nucleus Accumbens</term><term>Parkinson Disease</term></keywords><keywords scheme="MESH" qualifier="pathology" xml:lang="en"><term>Locus Coeruleus</term><term>Substantia Nigra</term></keywords><keywords scheme="MESH" qualifier="physiology" xml:lang="en"><term>Brain Chemistry</term></keywords><keywords scheme="MESH" xml:lang="en"><term>Aged</term><term>Autopsy</term><term>Case-Control Studies</term><term>Female</term><term>Humans</term><term>Male</term></keywords></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">Experimental findings using animal models of Parkinson disease (PD) suggest that noradrenaline might protect dopamine neurons from damage.</div></front></TEI><pubmed><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">17172611</PMID><DateCreated><Year>2006</Year><Month>12</Month><Day>18</Day></DateCreated><DateCompleted><Year>2007</Year><Month>01</Month><Day>23</Day></DateCompleted><DateRevised><Year>2013</Year><Month>11</Month><Day>21</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">0003-9942</ISSN><JournalIssue CitedMedium="Print"><Volume>63</Volume><Issue>12</Issue><PubDate><Year>2006</Year><Month>Dec</Month></PubDate></JournalIssue><Title>Archives of neurology</Title><ISOAbbreviation>Arch. Neurol.</ISOAbbreviation></Journal><ArticleTitle>Inverse relationship between brain noradrenaline level and dopamine loss in Parkinson disease: a possible neuroprotective role for noradrenaline.</ArticleTitle><Pagination><MedlinePgn>1724-8</MedlinePgn></Pagination><Abstract><AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">Experimental findings using animal models of Parkinson disease (PD) suggest that noradrenaline might protect dopamine neurons from damage.</AbstractText><AbstractText Label="OBJECTIVE" NlmCategory="OBJECTIVE">To assess whether human brain regions having high levels of noradrenaline are less susceptible to dopamine loss in PD.</AbstractText><AbstractText Label="DESIGN" NlmCategory="METHODS">Case-control study.</AbstractText><AbstractText Label="SETTING" NlmCategory="METHODS">Postmortem investigation.</AbstractText><AbstractText Label="PARTICIPANTS" NlmCategory="METHODS">Autopsied brains of patients with PD and of healthy control subjects. Main Outcomes Measures We compared the extent of dopamine loss in different regions relative to levels of noradrenaline found in healthy brain, with special attention devoted to the dopamine-rich nucleus accumbens, which has noradrenaline-rich and noradrenaline-poor subdivisions.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">Among 20 brain areas, dopamine loss in PD was negatively correlated with healthy noradrenaline levels (r = 0.83), with regions rich in noradrenaline (eg, the noradrenaline-rich portion of the nucleus accumbens) spared from dopamine loss. However, within the striatum, noradrenaline levels in the caudate and putamen were similar, despite dopamine's being more markedly reduced in the putamen.</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">Our postmortem data are consistent with animal findings suggesting that noradrenaline might affect dopamine neuron loss in PD and that a noradrenergic approach (although not aimed at the as yet unknown primary cause of PD) could be neuroprotective. This possibility should also be considered when noradrenergic therapy is provided for symptomatic purposes in PD.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Tong</LastName><ForeName>Junchao</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Human Neurochemical Pathology Laboratory, Centre for Addiction and Mental Health, Toronto, Ontario, Canada. junchao_tong@camh.net</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hornykiewicz</LastName><ForeName>Oleh</ForeName><Initials>O</Initials></Author><Author ValidYN="Y"><LastName>Kish</LastName><ForeName>Stephen J</ForeName><Initials>SJ</Initials></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>DA07182</GrantID><Acronym>DA</Acronym><Agency>NIDA NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Arch Neurol</MedlineTA><NlmUniqueID>0372436</NlmUniqueID><ISSNLinking>0003-9942</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000978">Antiparkinson Agents</NameOfSubstance></Chemical><Chemical><RegistryNumber>46627O600J</RegistryNumber><NameOfSubstance UI="D007980">Levodopa</NameOfSubstance></Chemical><Chemical><RegistryNumber>VTD58H1Z2X</RegistryNumber><NameOfSubstance UI="D004298">Dopamine</NameOfSubstance></Chemical><Chemical><RegistryNumber>X4W3ENH1CV</RegistryNumber><NameOfSubstance UI="D009638">Norepinephrine</NameOfSubstance></Chemical></ChemicalList><CitationSubset>AIM</CitationSubset><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000978" MajorTopicYN="N">Antiparkinson Agents</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001344" MajorTopicYN="N">Autopsy</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001923" MajorTopicYN="N">Brain Chemistry</DescriptorName><QualifierName UI="Q000502" MajorTopicYN="Y">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016022" MajorTopicYN="N">Case-Control Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D004298" MajorTopicYN="N">Dopamine</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007980" MajorTopicYN="N">Levodopa</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008125" MajorTopicYN="N">Locus Coeruleus</DescriptorName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009638" MajorTopicYN="N">Norepinephrine</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D009714" MajorTopicYN="N">Nucleus Accumbens</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D010300" MajorTopicYN="N">Parkinson Disease</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D013378" MajorTopicYN="N">Substantia Nigra</DescriptorName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2006</Year><Month>12</Month><Day>19</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2007</Year><Month>1</Month><Day>24</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2006</Year><Month>12</Month><Day>19</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">17172611</ArticleId><ArticleId IdType="pii">63/12/1724</ArticleId><ArticleId IdType="doi">10.1001/archneur.63.12.1724</ArticleId></ArticleIdList></PubmedData></pubmed></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Canada/explor/ParkinsonCanadaV1/Data/PubMed/Curation
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 001124 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/PubMed/Curation/biblio.hfd -nk 001124 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Canada
|area= ParkinsonCanadaV1
|flux= PubMed
|étape= Curation
|type= RBID
|clé= pubmed:17172611
|texte= Inverse relationship between brain noradrenaline level and dopamine loss in Parkinson disease: a possible neuroprotective role for noradrenaline.
}}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/PubMed/Curation/RBID.i -Sk "pubmed:17172611" \
| HfdSelect -Kh $EXPLOR_AREA/Data/PubMed/Curation/biblio.hfd \
| NlmPubMed2Wicri -a ParkinsonCanadaV1
| This area was generated with Dilib version V0.6.29. |  |